Related Experiment Video

Updated: Jun 7, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Regulation of tumor immunity by tumor/dendritic cell fusions

Shigeo Koido1, Sadamu Homma, Eiichi Hara

  • 1Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. shigeo_koido@jikei.ac.jp

Clinical & Developmental Immunology
|November 5, 2010
PubMed

Insights

Cancer vaccines aim to reduce tumor burden by stimulating antitumor immunity. This review explores tumor immune escape and dendritic cell (DC) fusion vaccines for enhancing T-cell responses against tumors.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Cancer vaccines strive to elicit antitumor immunity to reduce tumor burden.
  • Dendritic cell (DC)-based vaccines incorporating tumor-associated antigens (TAAs) are investigated globally.
  • While safe and capable of enhancing antitumor responses, DC-based vaccines show limited clinical success.

Purpose of the Study:

  • To review tumor immune escape mechanisms.
  • To examine current strategies for tumor/DC fusion vaccines.
  • To enhance the activation of TAAs-specific cytotoxic T cells within the tumor microenvironment.

Main Methods:

  • Literature review of tumor immune escape.
  • Analysis of dendritic cell (DC) fusion vaccine strategies.
  • Focus on enhancing T-cell responses against tumor-associated antigens (TAAs).

Main Results:

  • Limited success observed in clinical trials for DC-based vaccines.
  • Tumor immune escape remains a significant challenge.
  • Strategies are being developed to overcome these limitations.

Conclusions:

  • Tumor/DC fusion vaccines show potential for enhancing antitumor immunity.
  • Overcoming tumor immune escape is crucial for vaccine efficacy.
  • Further research is needed to optimize TAA-specific T-cell activation in the tumor microenvironment.

More Related Videos

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...